Dipna Pharmachem Ltd
Incorporated in 2011, Dipna Pharmachem Ltd
is in the business of Pharmaceutical Trading[1]
- Market Cap ₹ 10.5 Cr.
- Current Price ₹ 4.00
- High / Low ₹ 18.9 / 3.62
- Stock P/E 4.29
- Book Value ₹ 23.7
- Dividend Yield 0.00 %
- ROCE 7.64 %
- ROE 5.22 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 0.16 times its book value
- Company's working capital requirements have reduced from 91.1 days to 55.6 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 9.13%
- Company has a low return on equity of 3.93% over last 3 years.
- Promoter holding has decreased over last 3 years: -48.1%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 17 | 20 | 30 | 31 | 73 | 100 | 164 | 125 | 129 | |
| Sales growth | +22% | +51% | +1% | +135% | +37% | +64% | -24% | +4% | |
| 16 | 20 | 30 | 31 | 71 | 98 | 161 | 121 | 124 | |
| Operating Profit | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 5 |
| OPM % | 2.4% | 2.4% | 1.5% | 1.3% | 3.0% | 2.4% | 2.1% | 3.0% | 3.9% |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 4 |
| Tax % | 14% | 40% | 0% | 60% | 26% | 34% | 24% | 32% | 26% |
| 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | |
| EPS in Rs | 0.06 | 0.03 | 0.06 | 0.02 | 1.21 | 0.62 | 0.45 | 0.40 | 1.00 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 9% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 165% |
| 3 Years: | 42% |
| TTM: | 171% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -27% |
| 1 Year: | -73% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 4% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 12 | 24 | 24 | 26 |
| Reserves | 0 | 0 | 1 | 1 | 2 | 12 | 13 | 14 | 36 |
| 5 | 6 | 10 | 12 | 10 | 16 | 19 | 17 | 13 | |
| 6 | 8 | 8 | 12 | 24 | 37 | 76 | 77 | 130 | |
| Total Liabilities | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 206 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 206 | |
| Total Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 206 |
Cash Flows
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| -3 | -2 | 3 | -21 | -5 | -9 | -18 | |||
| 0 | 0 | -0 | -0 | -0 | -0 | -0 | |||
| 3 | 2 | -3 | 26 | 14 | -4 | 19 | |||
| Net Cash Flow | 0 | 0 | -0 | 5 | 8 | -13 | 0 | ||
| Free Cash Flow | -3 | -2 | 3 | -21 | -5 | -9 | -18 | ||
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -693% | -618% | 148% | -893% | -157% | -246% | -347% |
Ratios
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 132 | 160 | 134 | 176 | 135 | 104 | 69 | 135 | 136 |
| Inventory Days | 112 | 66 | 70 | 89 | 34 | 72 | 86 | 88 | 144 |
| Days Payable | 142 | 148 | 105 | 145 | 123 | 139 | 172 | 243 | 375 |
| Cash Conversion Cycle | 103 | 78 | 99 | 120 | 46 | 38 | -17 | -20 | -95 |
| Working Capital Days | 3 | 6 | 44 | 47 | 37 | 108 | 80 | 137 | 56 |
| ROCE % | 8% | 5% | 3% | 17% | 9% | 7% | 7% | 8% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Commission Income Share of Total Revenue % |
|
|||
| Number of Related Party Counterparties count |
||||
| Related Party Purchases as % of Total Purchases % |
||||
| Related Party Sales as % of Total Sales % |
||||
| Trade Receivables Over 6 Months as % of Total % |
||||
Extracted by Screener AI
Documents
Announcements
- Intimation Of Book Closure Pursuant To Regulation 42 Of The SEBI (Listing Obligation And Disclosure Requirement) Regulation, 2015
-
Reg. 34 (1) Annual Report.
- Annual Report FY26; AGM 30 Sep 2026; RPT approvals up to ₹100 Cr each.
-
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
- Authorised capital raised to ₹32 Cr; material RPTs with five related entities; AGM on 30 Sept 2026.
-
Considered And Recommended The Material Related Party Transactions
- Authorised capital raised to ₹32 Cr; AGM on Sept 30, 2026 to approve related party transactions.
-
Board Meeting Outcome for Outcome Of Board Meeting & Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
- Authorised capital raised to ₹32 Cr from ₹28.5 Cr; material RPTs recommended; AGM on 30 Sept 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
Business Overview:[1]
DPL is a trader, importer, and exporter of industrial Chemical and Pharmaceutical Raw materials, APIs, Solvents, Excipients, Intermediates, and Formulations. It provides assistance in setting up contract manufacturing compliance for regulated, semi-regulated pharmaceutical companies with all the global benchmark parameters of certificates like WHO-GMP